Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats
- PMID: 18054245
- DOI: 10.1016/j.ejcts.2007.09.040
Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats
Abstract
Objective: Although left ventricular repair (LVR) has been widely performed, the initial improvement of LV function does not last because of LV remodeling. Recent studies have demonstrated that chymase, a local enzyme in the heart, promotes angiotensin II formation as well as activation of transforming growth factor (TGF)-beta, both of which facilitate myocardial fibrosis. Therefore, chymase blockade may play an important role in the prevention of cardiac remodeling after LVR. In this study, the effects of chronic chymase inhibition (Chy-I) after LVR were evaluated in a rat LV aneurysm model.
Methods: Rats that developed LV aneurysms 4 weeks after coronary artery ligation underwent LVR by plicating the LV aneurysm, and were randomized into two groups, the LVR group and the LVR + Chy-I group that received an oral chymase inhibitor (10 mg/kg/day) for 4 weeks.
Results: Echocardiography revealed better LV function in the LVR + Chy-I group than in the LVR group at 4 weeks. Four weeks after LVR, LV end-diastolic pressure and the time constant of LV isovolumic pressure decay, were significantly lower in the LVR+Chy-I group. The end-systolic pressure-volume relationship was higher in the LVR+Chy-I group. In the LVR+Chy-I group, mRNA expressions of TGF-beta1 and BNP significantly decreased in the LV myocardium. Histology showed reduced interstitial fibrosis in the LVR+Chy-I group.
Conclusions: Chronic chymase inhibition prevented myocardial fibrosis and preserved cardiac function after LVR. A chymase inhibition could be an important strategy for management after LV repair surgery.
Comment in
-
Can cardiac fibrosis be prevented? Mast cell inhibition versus anti-chymase activity.Eur J Cardiothorac Surg. 2009 Mar;35(3):553-4; author reply 554-5. doi: 10.1016/j.ejcts.2008.11.021. Epub 2009 Jan 13. Eur J Cardiothorac Surg. 2009. PMID: 19144534 No abstract available.
Similar articles
-
Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair.Circulation. 2004 Sep 14;110(11 Suppl 1):II174-9. doi: 10.1161/01.CIR.0000138348.77856.ef. Circulation. 2004. PMID: 15364859
-
Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats.Hypertens Res. 2006 Jan;29(1):57-64. doi: 10.1291/hypres.29.57. Hypertens Res. 2006. PMID: 16715654
-
Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.Circulation. 2003 May 27;107(20):2555-8. doi: 10.1161/01.CIR.0000074041.81728.79. Epub 2003 May 12. Circulation. 2003. PMID: 12742989
-
Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models.Pharmacol Ther. 2006 Dec;112(3):668-76. doi: 10.1016/j.pharmthera.2006.05.008. Epub 2006 Jul 11. Pharmacol Ther. 2006. PMID: 16837049 Review.
-
Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis.Hypertens Res. 2005 Jun;28(6):483-90. doi: 10.1291/hypres.28.483. Hypertens Res. 2005. PMID: 16231753 Review.
Cited by
-
Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters.Respir Res. 2010 Mar 31;11(1):36. doi: 10.1186/1465-9921-11-36. Respir Res. 2010. PMID: 20356378 Free PMC article.
-
Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart.Sci Rep. 2019 Jul 29;9(1):11004. doi: 10.1038/s41598-019-47369-0. Sci Rep. 2019. PMID: 31358823 Free PMC article.
-
New dynamic viewing of mast cells in pulmonary arterial hypertension (PAH): contributors or outsiders to cardiovascular remodeling.J Thorac Dis. 2018 May;10(5):3016-3026. doi: 10.21037/jtd.2018.05.59. J Thorac Dis. 2018. PMID: 29997969 Free PMC article.
-
Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.Pharmacol Ther. 2011 Sep;131(3):338-50. doi: 10.1016/j.pharmthera.2011.04.010. Epub 2011 May 12. Pharmacol Ther. 2011. PMID: 21605595 Free PMC article. Review.
-
The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19.Front Pharmacol. 2021 Jun 17;12:640185. doi: 10.3389/fphar.2021.640185. eCollection 2021. Front Pharmacol. 2021. PMID: 34220496 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources